Genetic Duo: ATP13A2 and GBA1 Interactions Fuel Neurodegeneration Parkinson’s disease (PD) ranks as the second most prevalent neurodegenerative disorder following Alzheimer’s disease, impacting more than 10 million individuals globally. The condition manifests thr

Genetic Duo: #ATP13A2 and #GBA1 Interactions Fuel #Neurodegeneration. M. Gu and H Bellen explain their findings. @bcmhouston.bsky.social #TexasChildrens
@molneurodegen.bsky.social @bcmgenetics.bsky.social #BCMPostDoc bioengineer.org/genetic-duo-...

It takes two: Genes ATP13A2 and GBA1 interact to drive neurodegeneration Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting more than 10 million people worldwide. People with this condition may experience tremo...

How do two altered genes, #ATP13A2 and #GBA1, in two different cell types lead to neurodegeneration? M. Gu and H Bellen explain their findings. @bcmhouston.bsky.social #TexasChildrens @molneurodegen.bsky.social @bcmgenetics.bsky.social #BCMPostDoc medicalxpress.com/news/2026-02...

Endlyz Therapeutics emerges with pipeline for Parkinson’s disease - PharmaTimes Research targets lysosomal function restoration for neurodegeneration

#EndlyzTherapeutics #Parkinsonsdisease #neurology #ParkinsonsResearch #lysosomalfunctionrestoration #neurodegeneration #MichaelJFoxFoundationforParkinsonsResearch #ATP13A2 #ATP10B #PARK9gene #QuantumAI #DementiaDiscoveryFund #OxfordScienceEnterprises #ParkinsonsUK
pharmatimes.com/news/endlyz-...